Just out of curiosity, if clinical holds are generally about patient safety, why would you have a partial clinical hold that does not affect any trial, a full clinical hold that does not affect any trial, and no clinical hold on NASH and cancer. So is leronlimab dangerous for some nonexistent HIV patients, dangerous for all nonexistent Covid patients, and safe for all NASH and cancer patients?

If Amarex messed up safety, why is leonlimab safe for some HIV protocols and all NASH, and cancer. Or is it because HIV and Covid patients have other therapeutic options like Gilead's drugs?

Or is this just some meaningless ass kissing with the FDA to show CYDY is now a good boy?